We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Unum Therapeutics Inc | NASDAQ:UMRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.35 | 2.35 | 2.40 | 0 | 01:00:00 |
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-230678
PROSPECTUS SUPPLEMENT NO. 1
TO PROSPECTUS DATED MAY 1, 2019
This Prospectus Supplement No. 1 supplements and amends the prospectus dated May 1, 2019 (the Prospectus), covering the offering, issuance and sale of up to a maximum aggregate offering price of $50,000,000 (the Maximum Offering Price) of our common stock that may be issued and sold under a sales agreement with Cowen and Company, LLC (the ATM Facility).
Effective as of December 1, 2020, we have reduced the Maximum Offering Price to $9,500,000. As of the date of this prospectus supplement, no shares have been sold under the ATM Facility.
You should read this prospectus supplement, together with additional information described under the headings Incorporation by Reference and Where You Can Find More Information in the Prospectus carefully before you invest in our securities.
Investing in our securities involves a high degree of risk. Before making any investment in these securities, you should consider carefully the risks and uncertainties described in the section entitled Risk Factors beginning on page S-2 of the Prospectus.
The date of this prospectus supplement is December 1, 2020.
1 Year Unum Therapeutics Chart |
1 Month Unum Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions